• Talha Badar, Muhammad Ali Khan, Aniko Szabo, William Drobyski, Saurabh Chhabra, Binod Dhakal, Timothy S Fenske, Mehdi Hamadani, Parameswaran Hari, James H Jerkins, Nirav N Shah, Bronwen E Shaw, and Anita D'Souza.
• BMT & Cellular Therapy Program, Division of Hematology/Oncology, Medical College of Wisconsin , Milwaukee , WI , USA.
• Amyloid. 2019 Dec 1; 26 (4): 210-215.

AbstractEngraftment syndrome (ES), a complication of autologous hematopoietic cell transplantation (auto-HCT), can occur around the time of neutrophil recovery. We sought to identify the incidence of ES in light chain (AL) amyloidosis patients undergoing auto-HCT at our centre by evaluating 72 consecutive amyloidosis patients transplanted between 1999 and 2017. To assess trends in ES over time, patients were divided into two Eras (Era 1 = 1999-2008 and Era 2 = 2009-2017) based on year of auto-HCT. Twenty-two (31%) patients developed ES; three (16%) and 19 (36%) in Era 1 and 2, respectively (p = .1). Three (16%) and 51 (96%) patients in Era 1 and 2 received chemotherapy before auto-HCT (p =  <.001). The most common symptoms observed with ES in addition to fever was diarrhoea (73%), rash (68%), weight gain (56%) and non-cardiogenic pulmonary oedema (23%). Day 100 post-auto-HCT haematological response (19.5% vs. 14%, p = .7) or post-transplant best organ response (23% vs. 36%, p = .2) were not significantly different in patients who did not or did develop ES, respectively. In this single centre series, we define the incidence and characteristics of ES in AL amyloidosis patients undergoing auto-HCT.

25 keywords...

hide…